Campos-Fernández MM, Ponce-de-León-Rosales S, Archer-Dubon C, Orozco-Topete R

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 770-774
Archivo PDF: 53.16 Kb.

RESUMEN

Se realizó un estudio de cohorte en la Unidad de Terapia Intensiva (UTI) de un hospital de tercer nivel para evaluar la incidencia de reacciones cutáneas adversas a drogas. Se exa-minaron todos los pacientes internados en dicha unidad durante un periodo consecutivo de ocho meses. Observamos una incidencia de reacciones adversas a medicamentos de 11.6%. Los factores de riesgo asociados fueron sexo femenino, obesidad, edad mayor a 60 años y alteraciones inmunológicas (lupus eritematoso sistémico, distiroidismo y síndrome de antifosfolípido). Los antimicrobianos fueron los principales medicamentos involucrados. La erupción morbili-forme y la urticaria fueron las reacciones más frecuentes. Un hallazgo interesante fue que más de 50% de los pacientes con anasarca fallecieron. Concluimos que los pacientes internados en la UTI son particularmente susceptibles para desa-rrollar una reacción adversa cutánea a medicamentos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Breathnach SM. Adverse cutaneous reactions to drugs. Clin Med 2002; 2: 15-9.

2. Beltrani VS. Cutaneous manifestations of adverse drug reactions. Immunol Allergy Clin North Am 1998; 18: 867-95.

3. Cordoliani F. Eczemas. Rev Infirm 1988; 38: 29-32.

4. Lee A, Phil M, Pharm MR, Thomson J. Adverse drug reactions: Drug-induced skin reactions. Pharm Jour 1999; 262: 357-62.

5. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-74.

6. Vervloet D, Durham S. ABC of allergies: Adverse reactions to drugs. BMJ 1998; 316: 1511-4.

7. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-70.

8. Sonntag MR, Zoppi M, Fritschy D, Maibach R, Stocker F, Sollberger J, et al. Exanthema during frequent use of antibiotics and antibacterial drugs (penicillin, especially aminopenicillin, cephalosporin and cotrimoxazole) as well as allopurinol. Results of the Berne Comprehensive Hospital Drug Monitoring Program. Schweiz Med Wochenschr 1986; 116: 142-5.

9. Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Derm Venereol 1989; 69: 223-6.

10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.

11. Lang DM, Alpern MB, Visintainer PF, Smith ST. Gender risk for anaphylactoid reaction to radiographic contrast media. J Allergy Clin Immunol 1995; 95: 813-7.

12. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian Hospital –their severity and cost involved. Pharmacoepidemiol Drug Saf 2003; 12: 687-92.

13. Reiner DM, Frishman WH, Luftshein S, Grossman M. Adverse cutaneous reactions from cardiovascular drug therapy. N Y State J Med 1992; 92: 137-47.

14. Jick H, Porter JB. Potentiation of ampicillin skin reaction by allopurinol or hyperuricemia. J Clin Pharmacol 1981; 21: 456-8.

15. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-46.

16. Litt J, Pawlak W, editors. Drug Eruption Reference Manual. New York: Parthenon Publishing Group; 1999.

17. Cluff LE, Thornton CF, Seidl LG. Studies on the epidemiology of adverse drug reactions. I. Method of surveillance. JAMA 1964; 188: 976-83.

18. McKinney PA, Alexander FE, Cartwright RA, Ricketts J. The Leukaemia Research Fund data collection survey: the incidence and geographical distribution of acute myeloid leukemia. Leukemia 1989; 3: 875-9.

19. Kurtz KM, Beatty TL, Adkinson NF Jr. Evidence for familial aggregations of immunologic drug reactions. J Allergy Clin Immunol 2000; 105: 184-5.

20. Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996; 15: 217-27.

21. Pullen H, Weight N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; 2: 1176-8.

22. Becker LC. Allergy in systemic lupus erythematosus. Johns Hopkins Med J 1973; 133: 38-44.

23. Dover JS, Johnson RA. Cutaneous manifestations of human immunodeficiency virus infection. Part I. Arch Dermatol 1991; 127: 1383-91.

24. Wintroub BU, Stern RS. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167-79.

25. Adkinson NF Jr. Risk factors for drug allergy. J Allergy Clin Immunol 1984; 74: 567-72.

26. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthema subitum. Lancet 1988; 1: 1065-7.

27. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278: 1895-906.

28. Kauppinen K, Stubb S. Drug eruptions: causative agents and clinical types. A series of in-patients during a 10-year-period. Acta Derm Venereol 1984; 64: 320-4.

29. Shapiro LE, Shear NH. Drug interactions: Proteins, pumps, and P-450s. J Am Acad Dermatol 2002; 47: 467-84.

30. Asakura E, Mori K, Komori Y, Takano M, Hasegawa T, Kobayashi W, et al. The trend of the drug eruptions in the last fifteen years. Yakugaku Zasshi 2001; 121: 145-51.

31. Walker J, Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing 1994; 23: 255-9.

32. Bork K, editor. Cutaneous side effects of drugs. Philadelphia: WB Saunders; 1988.

33. Brawn LA, Castleden CM. Adverse drug reactions: an overview of special considerations in the management of the elderly patient. Drug Saf 1990; 5: 421-35.

34. Miller RR. Drug surveillance utilizing epidemiological methods: a report from the Boston Collaborative Drug Surveillance Program. Am J Hosp Pharm 1973; 30: 584-92.

35. The Bantam Medical Dictionary. New York: Market House Books Ltd; 1990, p. 131.